deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT00090064

MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

Phase II Clinical Trial Testing the Safety and Efficacy of 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in Subjects With Chronic Posttraumatic Stress Disorder

Sponsor: Lykos Therapeutics

Conditions Posttraumatic Stress Disorder
Interventions Lactose placebo pill Midomafetamine HCl Therapy
Updated 20 times since 2017 Last updated: May 23, 2025 Started: Mar 12, 2004 Primary completion: May 2, 2008 Completion: Jun 21, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Posttraumatic Stress Disorder, this trial is completed. The trial is conducted by Lykos Therapeutics and has accumulated 20 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jun 2023 · 5 months · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Nov 2023 · 3 months · monthly snapshot~Nov 2023 – ~Feb 2024 · 3 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jul 2025 · 7 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Jul 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Dec 2024 — Jul 2025 [monthly]

    Completed PHASE2

  4. Sep 2024 — Dec 2024 [monthly]

    Completed PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

▶ Show 15 earlier versions

  1. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE2

  2. Feb 2024 — Mar 2024 [monthly]

    Completed PHASE2

  3. Nov 2023 — Feb 2024 [monthly]

    Completed PHASE2

  4. Aug 2023 — Nov 2023 [monthly]

    Completed PHASE2

  5. Jun 2023 — Aug 2023 [monthly]

    Completed PHASE2

  6. Jan 2023 — Jun 2023 [monthly]

    Completed PHASE2

  7. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  8. Sep 2022 — Dec 2022 [monthly]

    Completed PHASE2

  9. Dec 2021 — Sep 2022 [monthly]

    Completed PHASE2

  10. Nov 2021 — Dec 2021 [monthly]

    Completed PHASE2

  11. Sep 2021 — Nov 2021 [monthly]

    Completed PHASE2

  12. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE2

  13. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  14. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  15. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lykos Therapeutics
Data source: Lykos Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations